Silence Therapeutics prices $175M public offering at $13.50 per ADS

Silence Therapeutics plc recently completed an underwritten public offering of 12,962,963 American Depositary Shares (ADS), each representing three ordinary shares valued at £0.05 in the company's capital. The ADS were priced at $13.50 per share, resulting in an approximate gross offering of $175 million prior to deducting underwriting discounts, commissions, and other related expenses.

Underwriters were granted a 30-day option to purchase up to an additional 1,944,444 ADSs at the offering price, less any applicable underwriting discounts and commissions. The offering is set to close on or around Thursday, contingent upon the fulfillment of customary closing conditions. Serving as the joint book-running managers for the offering are Jefferies, Morgan Stanley, Cantor, and William Blair.

The prospectus supplement and accompanying prospectus, integral components of the registration statement filed with the U.S. Securities and Exchange Commission (SEC) on May 18, 2026, were declared effective on May 27, 2026. This offering is being executed through a prospectus supplement and accompanying prospectus.

Silence Therapeutics is a clinical-stage biotechnology firm specializing in the development of short interfering RNA (siRNA) therapies. The company leverages its proprietary siRNA technology platform to create targeted therapies aimed at silencing disease-causing genes.